Cell News and Research

RSS

Life Technologies acquires Navigenics

Life Technologies Corporation today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies' first step in executing against a strategy to build out its molecular diagnostics business through internal development, partnerships and select acquisitions.

17 Jul 2012

Scientists discover new way to convert cord blood cells into iNC

For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.

17 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Scientists develop first cell-based model of Alzheimer's disease

A team of scientists at The New York Stem Cell Foundation (NYSCF) Laboratory led by Scott Noggle, PhD, NYSCF-Charles Evans Senior Research Fellow for Alzheimer's Disease, has developed the first cell-based model of Alzheimer's disease (AD) by reprogramming skin cells of Alzheimer's patients to become brain cells that are affected in Alzheimer's.

17 Jul 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

Cadherin-catenin-actin structure exerts force inside and between cells in living tissues

If you place certain types of living cells on a microscope slide, the cells will inch across the glass, find their neighbors, and assemble themselves into a simple, if primitive tissue. A new study at Stanford University may help explain this phenomenon, and then some, about the mechanical structure and behavior of complex living organisms.

17 Jul 2012

New CD141hi DC subset plays a critical role in activating immune response against pathogens

Scientists at A*STAR's Singapore Immunology Network (SIgN), in collaboration with Newcastle University, UK, the Singapore Institute of Clinical Sciences and clinicians from multiple hospitals in Singapore, have identified a new subset of dendritic cells (DCs) in human peripheral tissue which have a critical role in activating our immune response against harmful pathogens.

17 Jul 2012

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development.

17 Jul 2012

Research reveals how metformin reduces HCC risk

For every year that a patient with diabetes takes metformin, their risk for hepatocellular carcinoma reduces, say the authors of a study that also sheds light on the cellular pathway it uses.

16 Jul 2012

Treatment deteriorates giant cell arteritis imaging sensitivity

Patients with suspected giant cell arteritis should undergo imaging before or as soon as possible after treatment has started to minimize the chance of a false–negative result, advise German researchers.

16 Jul 2012

Mitochondrial gene regulators involved in Huntington’s disease pathology

Researchers have identified two molecules involved in mitochondrial function that appear to be important in the pathogenesis of Huntington’s disease.

16 Jul 2012

Osteoporosis and sarcopenia: researchers at UMKC receive $8.3 million to study relationship

The University of Missouri-Kansas City has received a five-year, $8.3 million grant from the National Institute on Aging, part of the National Institutes of Health, to study the relationship between osteoporosis (loss of bone density) and sarcopenia (loss of muscle mass) as people age.

16 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Elsevier introduces PLD solution for professionals in the life sciences

Elsevier, a world-leading provider of scientific, technical, and medical information products and services, today announced the launch of a structured Product Literature Database (PLD) solution for professionals in the life sciences.

16 Jul 2012

Polio eradication: an interview with Dr. Kathleen O’Reilly

Polio is a disease caused by a virus and results in paralysis, usually in the legs, of those affected. The paralysis is irreversible. In some extreme cases the virus spreads to the nerve cells of the brain reducing breathing capacity and this rarer form can be fatal.

16 Jul 2012

UMMS scientists identify new genetic mutation that causes familial ALS

A new genetic mutation that causes familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease, has been identified by a team of scientists led by researchers at the University of Massachusetts Medical School (UMMS).

16 Jul 2012

Novel way to monitor real-time chemical changes in brains of patients undergoing DBS

Mayo Clinic researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation (DBS). The groundbreaking insight will help physicians more effectively use DBS to treat brain disorders such as Parkinson's disease, depression and Tourette syndrome.

16 Jul 2012

Rehabilitation after rotator cuff surgery may be partially to blame for high rates of failed healing

A new Hospital for Special Surgery study suggests that the current rehabilitation used for patients undergoing tendon-bone repairs such as rotator cuff repair may be partially to blame for the high rates of failed healing after surgery. Experiments in a rat model of this injury suggest that immobilizing the limb for four to six weeks after surgery, rather than quickly starting physical therapy, improves healing.

16 Jul 2012